Vulture Conservation Action Plan

The Vulture Conservation Action Plan is the Government of India's principal policy instrument for arresting and reversing the catastrophic decline of vulture populations on the subcontinent. Its origins lie in the documented collapse of three resident Gyps species—the white-rumped vulture (Gyps bengalensis), the Indian vulture (Gyps indicus), and the slender-billed vulture (Gyps tenuirostris)—whose numbers fell by more than 97 percent during the 1990s. Scientific work led by the Bombay Natural History Society (BNHS) and the Peregrine Fund identified the veterinary anti-inflammatory drug diclofenac as the proximate cause: residues in cattle carcasses induced fatal renal failure and visceral gout in scavenging birds. The first formal Action Plan for Vulture Conservation in India was issued by the Ministry of Environment, Forest and Climate Change (MoEFCC) in 2006, and was succeeded by an expanded Action Plan covering the period 2020–2025, which broadened the policy to all nine vulture species recorded in the country.

The Plan operates through several interlocking procedural mechanisms. The foundational regulatory step was the prohibition of veterinary diclofenac: in 2006 the Drugs Controller General of India directed the phase-out of the veterinary formulation, and a 2015 order restricted human diclofenac to single-dose vials of three millilitres to prevent diversion to livestock use. Enforcement is delegated to drug inspectors and state animal-husbandry departments. The second mechanism is ex-situ conservation through a network of Vulture Conservation Breeding Centres (VCBCs), the flagship being the centre at Pinjore, Haryana, run jointly by BNHS and the Haryana Forest Department, alongside centres at Rajabhatkhawa (West Bengal) and Rani (Assam). These facilities maintain founder populations, breed birds in captivity, and prepare cohorts for eventual reintroduction once the environment is demonstrably toxin-free.

A third pillar is the territorial designation of Vulture Safe Zones (VSZs)—landscapes of roughly 100-kilometre radius around breeding colonies or release sites within which the use of toxic veterinary drugs is monitored and suppressed through pharmacy surveys, sampling of ungulate carcasses, and community sensitisation. The 2020–2025 Plan added measures to expand surveillance of additional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) found to be nephrotoxic to vultures, including aceclofenac, ketoprofen, nimesulide, and flunixin, while promoting meloxicam as the only veterinary NSAID tested and confirmed safe for Gyps species. The Plan also establishes a national Vulture Recovery Committee, mandates periodic population surveys, and calls for at least one VSZ in every state holding vulture populations.

Contemporary implementation has produced concrete institutional milestones. In 2020 the MoEFCC released the Action Plan for Vulture Conservation 2020–2025 under the stewardship of the National Board for Wildlife. India's first Vulture Conservation and Breeding Centre dedicated to a state, the Jatayu Conservation Breeding Centre at Pinjore, has bred and released white-rumped vultures fitted with satellite tags in Haryana since 2016. In 2023 Madhya Pradesh and Tamil Nadu undertook synchronised vulture census exercises, and a Vulture Conservation Centre was sanctioned at Pakke Tiger Reserve in Arunachal Pradesh. The Combined Drugs Controller and state regulators in Maharashtra and Gujarat have conducted pharmacy audits within VSZs straddling the western Ghats and the Saurashtra grasslands.

The Vulture Conservation Action Plan must be distinguished from adjacent conservation instruments. Unlike Project Tiger or Project Elephant, it is not a centrally sponsored scheme with a dedicated standing budget line but a policy and coordination framework executed largely through state forest departments and NGO partnerships. It is narrower than the National Wildlife Action Plan, which sets cross-cutting biodiversity priorities, and it is the domestic counterpart to the regional SAVE (Saving Asia's Vultures from Extinction) consortium and the Convention on Migratory Species (CMS) Multi-species Action Plan to Conserve African-Eurasian Vultures (Vulture MsAP) adopted in 2017. Whereas the Wildlife (Protection) Act, 1972 confers species protection by listing vultures in Schedule I, the Action Plan supplies the operational strategy that statutory listing alone cannot deliver.

Several controversies and edge cases persist. Enforcement of the diclofenac ban remains uneven because the permitted human-use multi-dose formulations continue to be diverted to cattle in some districts, and newly marketed NSAIDs frequently outpace toxicological testing. The question of when to commence large-scale releases from captive breeding stock is contested, since reintroduction is justified only once landscape carcass-sampling confirms negligible NSAID contamination—a threshold not yet met in most regions. Reintroduced birds carry the risk of resorting to contaminated provisioning sites, and a single poisoned carcass can kill dozens of birds at a communal feeding event, making the margin for regulatory error extremely narrow.

For the working practitioner—whether a civil-services aspirant preparing General Studies Paper III, an environment-ministry desk officer, or a conservation policy analyst—the Vulture Conservation Action Plan exemplifies how a single anthropogenic chemical can drive a keystone scavenger guild toward functional extinction, with cascading public-health consequences including feral-dog proliferation and elevated rabies risk where carrion is no longer cleared. It demonstrates the interplay between drug-regulation authorities, wildlife law, captive-breeding science, and landscape-scale community engagement. Mastery of its mechanics, named centres, the meloxicam-versus-diclofenac distinction, and its linkage to the CMS Vulture MsAP equips the practitioner to assess one of South Asia's most instructive ecological recovery efforts.